Yükleniyor... / Loading...
This study uses spatial radiomics and transcriptomics to explore the link between colon cancer and chronic kidney disease. Adults aged 18 and older with stage I or II colorectal cancer who are eligible for surgery, both with and without chronic kidney disease, may take part. Conducted by the National Cancer Institute, Naples, this study without an assigned phase is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Age ≥ 18 years * Life expectancy greater than 3 months \*\* * Histopathological diagnosis of colorectal cancer stage I or II according to the TNM (Tumor, Node, Metastasis) classification * Patients with tumors classified as T1-T3, N0, M0 (stage I-II) eligible for surgery * Ability to understand and sign the informed consent * Clinically stable patients with no significant changes in renal function or disease management in the weeks prior to enrollment \*\* For the non-CKD group • Adequate liver, renal and bone marrow function (adequate levels of hemoglobin, platelets, creatinine and bilirubin) For the CKD group * Confirmed diagnosis of chronic kidney disease according to the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines defined by a duration of at least three months with structural or functional abnormalities of the kidneys * BSA (Body Surface Area Area) eGFR≤60 ml/min/1.73 m2 Exclusion Criteria: * Recent episodes of acute renal failure * Kidney transplant, autoimmune diseases; inflammatory bowel diseases; other than oncological or oncohematological diseases of CRC * Recent therapies with steroids/immunosuppressants and cardiovascular events (within 3 months of enrollment) * History of serious allergic reactions to iodinated contrast agents or gadolinium-based contrast agents * Recent or planned invasive or surgical treatments that could interfere with the study (within 3 months of enrollment) * Psychiatric disorders that could impair the patient's ability to follow study procedures or provide informed consent * Other types of concomitant or previous tumors in the previous 5 years of enrollment * Pregnant or breastfeeding women. Pregnancy status will be ascertained before enrollment by measuring Beta-hCG in urine (Pregnancy Test or urinary beta-HCG) or in blood (plasma beta-hCG).